Division of Cellular and Molecular Therapy, Department of Pediatrics, University of Florida, Gainesville, FL, USA.
Atsena Therapeutics, Inc., Durham, NC, USA.
Transl Vis Sci Technol. 2023 Feb 1;12(2):2. doi: 10.1167/tvst.12.2.2.
To identify challenges and opportunities for the development of treatments for Usher syndrome (USH) type 1B.
In September 2021, the Foundation Fighting Blindness hosted a virtual workshop of clinicians, academic and industry researchers, advocates, and affected individuals and their families to discuss the challenges and opportunities for USH1B treatment development.
The workshop began with insights from individuals affected by USH1B. Presentation topics included myosin VIIA protein function in the ear and eye and its role in disease pathology; challenges with the USH1B mouse model most used in disease research to date; new investigations into alternative disease models that may provide closer analogues to USH1B in the human retina, including retinal organoids and large animal models; and learnings from and limitations of available disease natural history data. Participants discussed the need for an open dialogue between researchers and regulators to design USH1B clinical trials with appropriate outcome measures of vision improvement, along with multimodal imaging of the retina and other testing approaches that can help inform trial designs. The workshop concluded with presentations and a roundtable reviewing emerging treatments, including USH1B-targeted genetic augmentation therapy and gene-agnostic approaches.
Initiatives like this workshop are important to foster all stakeholders in support of achieving the shared goal of treating and curing USH1B.
Presentations and discussions focused on overcoming disease modeling and clinical trial design challenges to facilitate development, testing, and implementation of effective USH1B treatments.
确定 1B 型乌谢尔综合征(USH)治疗方法开发的挑战和机遇。
2021 年 9 月,盲症基金会举办了一次虚拟研讨会,邀请临床医生、学术和行业研究人员、倡导者以及受影响的个人及其家属参加,讨论 1B 型 USH 治疗开发的挑战和机遇。
研讨会首先由受 1B 型 USH 影响的个人分享见解。演讲主题包括肌球蛋白 VIIA 蛋白在耳和眼的功能及其在疾病发病机制中的作用;迄今为止用于疾病研究的最常用的 1B 型 USH 小鼠模型所面临的挑战;对替代疾病模型的新研究,这些模型可能在人类视网膜中提供更接近 1B 型 USH 的模拟物,包括视网膜类器官和大型动物模型;以及现有疾病自然史数据的经验教训和局限性。参与者讨论了研究人员和监管机构之间需要进行开放对话,以设计具有适当视觉改善结果衡量指标的 1B 型 USH 临床试验,以及视网膜的多模态成像和其他有助于告知试验设计的测试方法。研讨会最后进行了介绍和小组讨论,回顾了新兴的治疗方法,包括针对 1B 型 USH 的基因增强治疗和基因不可知方法。
像这样的研讨会对于促进所有利益相关者的支持,实现治疗和治愈 1B 型 USH 的共同目标非常重要。
重点介绍了克服疾病建模和临床试验设计挑战的举措,以促进有效治疗 1B 型 USH 的开发、测试和实施。